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Background: Nutritional parameters represent modifiable factors
to improve outcomes after HSCT. Pediatric studies linking weight
to survival are over 10 years old, and analyses of prealbumin (PAB)
levels have not examined the impact on survival.
Methods:We conducted a retrospective chart review of all pediatric
HSCT at our institution from 7/1/2007 to 6/30/2011 (N5 77).Wil-
coxon rank-sum test was used to compare weight characteristics as
well as PAB and albumin levels (admission, days 0, +7, +14,+28,
and +90 for albumin alone) between the autologous (auto) and allo-
geneic (allo) groups. Survival analyses utilized the Kaplan-Meier
method and the log-rank test to compare differences. Effects on sur-
vival were examined with a Cox proportional hazards model and
analyses of non-relapse mortality (NRM) incorporated competing
risks.
Results: Mean weights as % of ideal body weight at admission
were above 100% and not significantly different between the auto
and allo groups (p 5 0.80). BMI at admission was not significantly
different between the auto and allo groups (19.5 and 19.3 respec-
tively, p 5 0.97). At day +30, the auto group had greater % weight
loss than the allo group with mean weight loss of 1.7% (p 5 0.01).
In the auto group, weight loss at day +30 was associated with sig-
nificantly worse day +100 and 1 yr survival compared to those who
had weight gain (p 5 0.03). The lowest median PAB level was 13.8
mg/dL on day 0 for allo patients and 12.2 mg/dL on day +7 for
auto patients. Similarly, the lowest median albumin level was 2.9
g/dL on day 0 for allo patients and 2.8 g/dL on day +7 for auto pa-
tients. Differences between groups at these time points were statis-
tically significant (p\0.05). Univariate analyses identified PAB
levels below 15 mg/dL at day +7 as significantly decreasing day
+100 and 1 yr survival in the allo group (p 5 0.0003). Additionally,
allo patients with a PAB level below 12 mg/dL at any time between
day 0 to +14 had worse day +100 and 1 yr survival (p 5 0.023).
Multivariate analysis of the combined groups demonstrated a signif-
icant impact of decreased PAB levels between day 0 to +14 on
NRM, with a hazard ratio of 0.85 (95%CI 0.76-0.96, p 5 0.006).
Accordingly, this represents an increase in NRM risk of 120%
per 5 mg/dL decrease in PAB.
Conclusion: Nutritional support should be maximized early in the
transplant course. As PAB is decreased in the setting of inflamma-
tion, future studies should prospectively evaluate PAB in conjunction
with inflammatory markers.276
MOYAMOYA SYNDROME TREATED WITH ENCEPHALODUROARTERIOSY-
NANGIOSIS FOLLOWED BY HEMATOPOIETIC CELL TRANSPLANTATION
IN PATIENTS WITH SICKLE CELL DISEASE
Klein, O.1, Walters, M.2, George, D.3, Chu, R.4, Goodrich, J.T.5,
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ren’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx,
NY; 6New York Methodist Hospital, Brooklyn, NYTable 1. Supplemental Patient Data
Patient
Presenting Symptoms
of Initial CNS Event
Age at Diagnosis of
Moyamoya Syndrome Age at EDA
1 Seizures 11 years 6 months 12 years 2 mont
2 Visual changes 13 years 2 months Two-Step Proced
4 months and
3 Seizures 2 years 6 months 4 years 6 month
4 Left-Sided Hemiparesis 3 years 6 years 6 month
5 Seizures, Personality
Changes
7 years 6 months Two-Step Proced
years 10 mon
years 11 mon
6 Eye pain 6 years 11 years 9 montBackground: Patients with sickle cell disease (SCD) have a high risk
of intracranial large vessel vasculopathy, leading to a proliferation of
microvasculature at the base of the brain known as moyamoya syn-
drome. This confers a high risk of intraventricular hemorrhage
and permanent neurologic deficits. Moyamoya syndrome can be
treated surgically with a revascularization procedure called encepha-
loduroarteriosynangiosis (EDAS), which has been shown to decrease
but not eliminate the risk of stroke. Hematopoietic cell transplanta-
tion (HCT) from a compatible sibling is the most effective way of
preventing central nervous system (CNS) complications in SCD pa-
tients at risk for CNS events. There have been several reports of pa-
tients with SCD and moyamoya syndrome undergoing EDAS
successfully; however, there have been no reports of these patients
undergoing EDAS followed by HCT.
Results:We report six pediatric cases of patients with SCDwho de-
veloped moyamoya syndrome, all of whom underwent EDAS fol-
lowed by HCT. All patients underwent EDAS procedure
successfully. One patient experienced a stroke less than a month after
EDAS. Another patient developed a foot-drop post-EDAS, though
imaging did not show any new areas of infarct. All patients under-
went HLA-matched sibling-donor HCT. The chronic transfusion
therapy was successfully discontinued in the two patients who had
been on it prior to treatment. Post-transplant, one patient developed
seizures, with imaging consistent with possible infarct; the patient
was placed on antiepileptics and has not had subsequent seizures.
In all follow-up imaging, there has been no progression of the pa-
tients’ moyamoya syndrome.
Conclusion:These are the first reported cases of EDAS successfully
followed by HCT in patients with SCD and moyamoya syndrome.
Five of the six patients had no further CNS events, and all remained
neurologically stable, with no progression of their moyamoya syn-
drome. HCT is the standard of care in patients with SCD at risk
for CNS complications, leading to excellent stroke-free survival
rates. Patients with moyamoya syndrome and SCD are at high risk
of developing CNS complications. Transplant-eligible SCD pa-
tients who develop moyamoya syndrome may benefit from EDAS
prior to HCT in order to minimize CNS complications. Further in-
vestigation by way of an international, multicenter prospective study
is needed to determine the long-term outcome and potential benefits
of this therapeutic combination.277
COMPARISON OF SURVIVAL AND INCIDENCE OF GRAFT VERSUS HOST
DISEASE IN FULLY MATCHED, SINGLE C MISMATCHED AND OTHER MIS-
MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTS IN A PEDIATRIC POPULATION
Liney, D.1, Lee,M.A.2, Sun, P.1, London,W.B.1, Lehmann, L.E.2 1Dana
Farber Cancer Institute, Boston, MA; 2Dana- Farber/Children’s Hospital
Cancer Care, Boston, MA
It is well understood that undergoing hematopoietic stem cell
transplant (HSCT) froman unrelated (URD) compared to amatched
sibling donor (MSD) results in increased graft versus host disease
(GVHD) and for the pediatric population this often but not always
negatively impacts overall survival. In the current era of high resolu-
tion Class I / Class II typing there is a lack of clarity about the impactS Procedure Age at HCT Post-HCT Complications
hs 12 years 8 months Seizure, Possible Left Middle
Cerebral Artery Infarct
ure: 13 years
13 years 7 months
13 years 9 months None
s 5 years 6 months None
s 8 years 6 months None
ure: 8
ths and 8
ths
13 years None
hs 13 years 6 months None
S308 Poster Session Iof using donors that are not fully matched on both GVHD incidence
and overall survival. Historically there is evidence that an isolated C
mismatch may not affect these outcomes but this has been evaluated
almost exclusively in adult patients with hematologic malignancies.
We collected data on a 146 consecutive pediatric patients (median
age 9 years) who received an unrelated donor transplant at Children’s
Hospital Boston from 1/2004 through 12/2010 for malignant and
nonmalignant conditions. 97% received bone marrow as the stem
cell source and 97% received fully myeloablative conditioning.
75% underwent HSCT for a hematologic malignancy (leukemia/
lymphoma), 11% for immunodeficiency and the remainder for other
indications, primarily bone marrow failure syndromes. 70% of pa-
tients had a donor fully matched at both A,B,C,DR, DQ loci on
high resolution typing, 10% had a single C mismatch and the re-
maining 20% had a donor with 1 or 2 other mismatches excluding
a single C mismatch (none had a DR mismatch and all were at least
a 5/6 match on A, B, DR). 45% experienced GVHD: 13% acute
only, 51% chronic only and 32%both. There was no statistically sig-
nificant difference in the proportion of patients who had acute
GVHD of any grade and/or limited or extensive chronic GVHD be-
tween those having a fully matched, single C mismatch or other mis-
matched donor (p5 0.7). There was also no significant difference in
survival between the groups. 100 day and 1 year overall survival were
93%/77% with fully matched donors, 87%/60% for single C mis-
matched donors (p 5 0.2) and 96%/76% for other mismatched do-
nors. Thus it appears that in the era of high-resolution HLA typing
and improved supportive care HLA mismatched donors can provide
outcomes similar to those using fully matched donors in pediatric
patients undergoing HSCT for malignant and nonmalignant
conditions.Table 1. Association between AUC-all and AUC generated
by LSSs
Sample times
(hours after start of
infusion) Adjusted r2
Mean bias
(%; range) Precision (%)
2, 3 and 4 0.9962 0.05 (-5.3 to 4.6) 3.6
2, 3, 4 and 10 0.9981 0.03 (-2.0 to 2.0) 1.2
2, 2.5, 3, 4 and 10 0.9990 0.05 (-2.0 to 3.0) 0.9278
EPIDEMIOLOGY OF BACTERIAL, FUNGAL AND VIRAL INFECTIONS IN
CHILDREN AND ADOLESCENTS AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Srinivasan, A.1, Wang, C.2, Srivastava, D.K.2, Leung, W.H.1,
Hayden, R.T.3 1St.Jude Children’s Research Hospital, Memphis, TN;
2St.Jude Children’s Research Hospital, Memphis, TN; 3St.Jude Child-
ren’s Research Hospital, Memphis, TN
The epidemiology of bacterial, fungal and viral infections was
retrospectively analyzed in a cohort of 759 children and adolescents
who underwent allogeneic hematopoietic stem cell transplantation
(HSCT) in a single institution, between 1990-2009, to study the
impact of changes in transplantation methodology on the distribu-
tion of pathogens and mortality due to infections. There were 243
matched-related, 239 matched-unrelated (MUD) and 176 haplo-
identical donor transplants. Independent logistic regression was
conducted at 0-30 days (A), 30-100 days (B) and .100 days (C)
post-transplant. On multivariate analysis, total body irradiation (p
5 0.001, A; 0.005, C), apheresis product (p 5 0.02, A; 0.01, B),
acute (p 5 0.002, B) and chronic (p 5 0.03, C) graft vs host disease
(GVHD) were associated with higher risk for bacterial infections at
the respective time periods. CMV serostatus (p 5 0.05, B), pres-
ence of acute (p 5 0.001, B), chronic GVHD (p\0.001, C) and
age .10 yrs (p 5 0.02, C) were associated with higher risk for fun-
gal infections. CMV serostatus (p 5 0.0005, A; 0.03 B; 0.002 C),
acute (p 5 0.01, A) and chronic GVHD (p 5 0.001, C), were asso-
ciated with higher risk for viral infections. MUD donor transplants
were associated with a higher risk of viral infections (p 5 0.001).
Bacterial (p 5 0.002) and fungal (p 5 0.0004) infections in period
A, decreased in the 2005-2009 era. There were 321 episodes of bac-
teremia in 231(30%) patients, of whom 168 episodes (52%) were in
period C. Staphylococcus epidermidis (33%) and Escherichia coli (12%)
were the most common causes of bacteremia. Candidemia, mostly
C.albicans, was detected in 49 (6%) patients, 26 (54%) in period C.
There were 45 patients with proven aspergillosis, 20 (44%) in pe-
riod A. Non-aspergillus molds were detected in 16 (2%) patients.
CMV and adenoviremia was detected in 146 (20%) and 68 (9%)
patients respectively. Parainfluenza was the most common respira-
tory viral infection detected in 70 (9%) patients, 35(50%) in period
C. This is the largest retrospective study providing a time line of
infections in children and adolescents who have undergone alloge-
neic HSCT.279
CYCLOSPORINE AREA UNDER THE CURVE IN CHILDREN UNDERGOING
HAEMATOPOIETIC STEM CELL TRANSPLANTATION: LIMITED SAMPLING
STRATEGY AT STEADY-STATE
Schechter, T.1, Teuffel, O.1, Gibson, P.2, Sung, L.1, Seto,W.3, Gassas, A.1,
Doyle, J.1, Dupuis, L.L.1 1The Hospital for Sick Children, Toronto, ON,
Canada; 2London Health Sciences Centre, London, ON, Canada; 3The
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Haematopoietic stem cell transplantation (HSCT) outcomes may
be optimized by cyclosporine dose adjustment according to systemic
exposure (measured by area under the curve (AUC)) rather than
trough concentration. We have previously developed and validated
a limited sampling strategy (LSS) for estimating cyclosporine AUC
after the initial IV dose in children undergoing HSCT. In this study
we aim to develop a LSS to estimate AUC at steady-state.
Children undergoing myeloablative HSCT and given cyclospor-
ine q12h as a 2-hour infusion and methotrexate/methylprednisolone
for acute graft-versus-host disease (GVHD) prophylaxis were eligi-
ble. Cyclosporine AUC was determined once weekly until engraft-
ment using 9 concentration-time points. Steady state was defined
as being reached after administration of 4 identical doses.
The association between cyclosporine AUC using all available
data points (AUC-all) and the AUC values predicted by each LSS
was described using the adjusted coefficient of determination (r2);
values . 0.9 were acceptable. Precision and mean bias \ 15%
were acceptable.
18 children (0.3-17 years) participated. Mean actual dose infu-
sion time was 1236 4.4 min. Mean AUC-all at steady state was
489461386 h*mcg/L. Individual cyclosporine whole blood concen-
trations drawn at 2, 2.5, 3, and 4 hours after the start of the infusion
correlated most highly with AUC-all (Spearman rho coefficient:
0.847, 0.926, 0.942, and 0.903, p\0.0001, respectively). Values of
AUC predicted by the 3, 4 and 5-point LSS were strongly associ-
ated with AUC-all (spearman rho coefficient . 0.998;
p\0.0001).The 3-point LSS (2, 3 and 4 hours) is likely the method
of choice for determining cyclosporine AUC at steady state when
given as 2 hour infusion to children undergoing HSCT. Validation
of the LSS in a different sample is required before this LSS strategy
can be implemented. The relationship between acute GVHD and
cyclosporine AUC at different time periods after HSCT merits
further study.280
THROUGH THEIR EYES: THE EXPERIENCES OF THE MINOR AND YOUNG
ADULT MATCHED SIBLING HEMATOPOIETIC CELL DONORS – A RETRO-
SPECTIVE STUDY FROM A SINGLE REGIONAL INSTITUTION
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Matched sibling donor hematopoietic cell transplantation (HCT)
is considered the standard of care for many disorders, yet the donor’s
emotional and physical needs may be overlooked and the donor
viewed as a therapeutic modality in the process of saving the life of
an ill sibling. In this IRB-approved study, we explored the meaning
of the donor’s experiences through his own words and recollections,
and the contextual influences and critical events across the transplant
trajectory. A semi-structured interview was conducted in private
